As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

On Feb. 27, Blackstone disclosed that Rodney Zemmel – a long-time Senior Partner at McKinsey, who served as the global leader of both McKinsey Digital and the firm’s AI Transformation initiatives – ...

An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as ...

It was perhaps not the welcome Irish Prime Minister Micheal Martin had hoped for on an annual US trip to mark Saint Patrick's ...

U.S. drugmakers Johnson & Johnson and Eli Lilly increased spending on security for their top executives in 2024, citing ...

Artificial intelligence (AI) and the Internet of Things (IoT) are about to revolutionize the biopharmaceutical industry.

Roche (RHHBY) is increasing its investment into the obesity space with an up to $5.3 billion deal with Danish drugmaker ...

Then it’s off to work, spending much of his time visiting Eli Lilly and Co. manufacturing sites and those ... Every unit has 70 to 80 pictures taken of them through high-speed automatic visual ...

Eli Lilly and Incyte's baricitinib showed significant hair regrowth in adolescents with severe alopecia areata, with results ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.